Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal trial of jCell in retinitis pigmentosa

Next Previous
Trial Profile

A Pivotal trial of jCell in retinitis pigmentosa

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Feb 2024 According to a jCyte media release, the company announced successful outcome of its pre-phase 3 Type B meeting with the US Food and Drug Administration (FDA) held on January 16, 2024.Also the company will initiate trial for jCell in the second half of 2024.
  • 15 Nov 2021 According to a jCyte media release, the application of key findings from phase 2b study in RP will help the company maximize the probability of success of the pivotal Phase 3 RP trial program without significantly limiting the potential pool of study candidates, since most RP patients have greater than 20 degrees of central visual field and a central subfield mean thickness of greater than 130 microns.
  • 29 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top